A new and innovative approach to the treatment of interstitial cystitis TORONTO, May 12 /PRNewswire/ - Trillium Therapeutics Inc., a privately-held biopharmaceutical company, announced today that it has raised $1 million from a new undisclosed investor.

MORRISTOWN, N.J., Nov. 10, 2010 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI) today announced that the U.S. pilot study evaluating Uracyst® (sodium chondroitin sulfate solution 2.0%) for the treatment of interstitial cystitis did not meet predefined efficacy endpoints.

RARITAN, N.J., Oct. 20 /PRNewswire/ -- More than one million Americans - most of them women - suffer from a painful and little-known bladder condition called interstitial cystitis (IC).

Two U.S. physicians suggest allergy testing may help some who suffer from the painful bladder condition interstitial cystitis. Dr. John Hubbard, a urologist, and Dr. C.

Findings point to new treatment options and research directions WASHINGTON, June 19 /PRNewswire-USNewswire/ -- Allergy testing and treatment may offer a new therapeutic option for many patients with interstitial cystitis (IC).